Effects of Randomization to Intensive Glucose Control on Adverse Events, Cardiovascular Disease, and Mortality in Older Versus Younger Adults in the ACCORD Trial
Year: 2014
Type: article
Abstract: OBJECTIVE: We explore the effect of randomized treatment, comparing intensive to standard glucose-lowering strategies on major cardiovascular outcomes, death, and severe adverse events in older versus younger participants in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. RESEARCH DESIGN AND METHODS: Participants with type 2 diabetes (n = 10,251) with a mean age of 62 years, a median duration of diabetes of 10 years, and a median A1C of 8.1% (65 mmol/mol) were randomized to treatment strategies targeting either A1C <6.0% (42 mmol/mol) or 7.0-7.9% (53-63 mmol/mol) and followed for a mean of 3.7 years. Outcomes were analyzed within subgroups defined by baseline age (<65 vs. ≥65 years). RESULTS: Older and younger ACCORD participants achieved similar intensive-arm A1C levels and between-arm A1C differences. Within the older subgroup, similar hazards of the cardiovascular primary outcome and total mortality were observed in the two arms. While there was no intervention effect on cardiovascular mortality in the older subgroup, there was an increased risk in the intensive arm for the younger subgroup (older hazard ratio [HR] = 0.97; younger HR = 1.71; P = 0.03). Regardless of intervention arm, the older subgroup experienced higher annualized rates of severe hypoglycemia (4.45% intensive and 1.36% standard) than the younger subgroup (2.45% intensive and 0.80% standard). CONCLUSIONS: Intensive glucose lowering increased the risk of cardiovascular disease and total mortality in younger participants, whereas it had a neutral effect in older participants. The intensive to standard relative risk of severe hypoglycemia was similar in both age subgroups, with higher absolute rates in older participants within both treatment arms.
Source: Diabetes Care
DOI: 10.2337/dc13-1545
Authors: Michael E. Miller, Jeff D. Williamson, Hertzel C. Gerstein, Robert P. Byington, William C. Cushman, Henry N. Ginsberg, Walter T. Ambrosius, Laura Lovato, William B. Applegate, for the ACCORD Investigators
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Funders: Massachusetts General Hospital, Wake Forest University, State University of New York, Georgetown University, National Institutes of Health, Centers for Disease Control and Prevention, University of Texas Health Science Center at San Antonio, SUNY Downstate Medical Center, National Institute on Aging, National Heart, Lung, and Blood Institute, National Institute of Diabetes and Digestive and Kidney Diseases, Duke Clinical Research Institute
Awards: G1029652654, PREVENTION OF CARDIOVASCULAR DISEASE IN DIABETES MELLITUS, ACCORD, ACCORD, G1955785366, G2121141810, G2150788371, G217652925, ACCORD, G2535401525, G2556935141, ACCORD, G2717754883, G3186661918, G3534128112, G3792726805, G401067667, ACCORD, G4931486092, G6535417321, G6920961921, G7683729920, G77894727, G781655334, G8499292716, Wake Forest Claude D. Pepper OAIC - Renewal, PREVENTION OF CARDIOVASCULAR DISEASE IN DIABETES MELLITUS
OpenAlex ID: W2134625795
